Core Viewpoint - A Delaware judge has allowed a shareholder lawsuit alleging insider trading by Coinbase directors to proceed, despite a special committee's prior investigation clearing the defendants [1][2]. Group 1: Lawsuit Details - The lawsuit, initiated by shareholder Adam Grabski in 2023, claims that Coinbase directors used confidential valuation information to avoid over $1 billion in losses by selling shares during the company's direct listing in April 2021 [2]. - High-profile directors involved include CEO Brian Armstrong and venture capitalist Marc Andreessen, who collectively sold more than $2.9 billion in stock during the direct listing [1]. Group 2: Internal Investigation - The special litigation committee, consisting of board members Kelly Kramer and Gokul Rajaram, was found to have conflicts of interest, particularly concerning Rajaram's ties to Andreessen Horowitz, which undermined the committee's independence [3][4]. - Judge McCormick noted that while the internal investigation presented a strong defense for the directors, the substantial business connections between Rajaram and Andreessen raised material disputes regarding Rajaram's independence [2][4]. Group 3: Direct Listing Structure - Coinbase's direct listing allowed existing shareholders to sell shares immediately without the typical lockup periods associated with traditional IPOs, which are designed to prevent insider trading [6].

Core Insights - The anticipated IPO activity is expected to surge, particularly with companies like SpaceX potentially leading the way, as there are no longer excuses for remaining private by 2026 [1][2][12] - High-value private companies, previously reluctant to go public, are now indicating a willingness to pursue public listings, which could benefit both companies and investors [1][2] - The potential IPO of SpaceX, with a valuation target of up to $1.5 trillion, could significantly impact the public market landscape and challenge traditional valuation metrics [2][11] Company Insights - SpaceX is projected to generate approximately $15 billion in revenue in 2025, with expectations of growth to between $22 billion and $24 billion in 2026 [4] - The company has established itself as a leader in space exploration, being the only commercial US entity capable of launching humans to orbit and operating the largest satellite constellation for broadband internet [7] - However, going public may complicate SpaceX's capital-intensive projects, such as the development of the Starship rocket, as it would require addressing shareholder expectations for short-term profits [8][9] Market Dynamics - The IPO market has been stagnant since a record $492 billion in 2021, with many high-profile companies like SpaceX and Stripe remaining private due to high valuations in private funding rounds [2] - There is a significant pool of private companies, valued at approximately $2.9 trillion, that have avoided public listings, indicating a potential shift in market dynamics [3] - The prospect of large IPOs, particularly those exceeding $50 billion, could reshape annual listing volumes on US exchanges, as such deals have not been attempted before [13][15] Investor Sentiment - Investors are increasingly concerned about the governance and valuation of companies like SpaceX, especially given the leadership of Elon Musk and the potential for conflicts with his other ventures [5][12] - The need for liquidity and returns is driving some private firms toward public markets, as investors seek to manage their portfolios effectively [18][19] - The possibility of a direct listing is being considered for large private companies that do not necessarily need to raise capital, as they have established shareholder bases similar to public companies [15][16]

As filed with the Securities and Exchange Commission on December 9, 2025 Registration No. 333-275508 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 9 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FREECAST, INC. (Exact name of registrant as specified in its charter) Florida 7990 45-2787251 (State or other jurisdiction of incorporation or organization) (Primary standard industrial classification code number) 6901 TPC Drive, Suite 200 Orlando, Florid ...

Core Viewpoint - Sampo plc is transitioning from a Swedish Depositary Receipt (SDR) arrangement to a direct listing of its A Shares on Nasdaq Stockholm, aiming to enhance liquidity and streamline shareholder rights [2][4]. Group 1: Listing Transition - Sampo plc will request the termination of its SDR arrangement and apply for direct trading of its A Shares on Nasdaq Stockholm [2]. - The A Share has been listed through SDRs since November 22, 2022, with SEB as the issuer and market maker [3]. - Euroclear Sweden's recent policy change allows Sampo to pursue a direct listing, aligning with its existing listings on Nasdaq Helsinki and Nasdaq Copenhagen [3]. Group 2: Benefits of Direct Listing - The direct listing is expected to increase liquidity in the Swedish market for all issued A Shares and reduce the tick size compared to the SDRs [4]. - Current SDR holders will be able to exercise shareholder rights directly without SEB as an intermediary [4]. Group 3: Timeline and Important Dates - A formal termination notice for the SDR arrangement will be published around November 6, 2025 [5]. - The last trading day for SDRs is expected to be around February 13, 2026, with the first trading day for A Shares on February 16, 2026 [7]. - The record date for SDR conversion is set for February 17, 2026, and delivery of A Shares to SDR holders will occur on February 19, 2026 [7].

Core Insights - Turn Therapeutics is making significant progress in its clinical programs while maintaining a flexible financing strategy through a dilution-sparing direct listing [1][2][3] Capital Strategy and Alignment - The company opted for a direct listing to enhance flexibility and align with long-term shareholder interests, allowing early shareholders to retain their ownership [2] - Through an $85 million GEM Global Yield agreement, Turn has established a flexible financing mechanism that enables opportunistic capital access without the need for traditional offerings at the time of listing [3] Pipeline and Development Update - Turn is advancing its phase 2 trial of GX-03 for moderate to severe eczema, with approximately 25% of the targeted sample size having completed the trial and ongoing enrollment [4] - The study of GX-03, the first topical IL-36/IL-31 inhibitor, is on track, with topline results expected in 2026 and no safety concerns reported for the 25% of participants who have completed the trial [5] - The company is also progressing its thermostable intranasal vaccine initiative, with in-vivo studies set to begin in Q4 2025, reflecting its commitment to global health [6] Company Overview - Turn Therapeutics focuses on developing and commercializing products for dermatology, wound care, and infectious diseases, having received three FDA clearances for its proprietary formulations and advancing late-stage clinical programs [8]

Core Viewpoint - Sony Group's stock rose by 4% following the announcement of a spin-off of its financial services arm, with shareholders set to receive 80% of the newly created shares [1][2]. Group 1: Spin-off Details - Sony is spinning off its financial services arm due to a change in Japanese tax law, which allows for a tax-free partial spin-off [2][3]. - This spin-off will be the first partial spin-off under the 2023 tax law and the first direct public listing in Japan in over 20 years [3]. Group 2: Shareholder Benefits - Current Sony shareholders will benefit significantly as they will receive 80% of the shares from the new entity, which has positively impacted the stock price [2]. - More details regarding the growth plan for the newly created company will be disclosed during the upcoming Investor Day [2]. Group 3: Strategic Focus - The spin-off allows Sony to streamline its operations and refocus on its core businesses, which include entertainment and consumer electronics [5]. - This strategic move is expected to free up capital for investment in key areas such as image sensors, which are crucial for smartphones [5]. - Sony possesses solid growth prospects and valuable intellectual property in entertainment, along with a proven record of innovation in consumer electronics [5].